IP Library › Granted Patent US 10,449,151
Granted Patent B2
US 10,449,151 · App. 15/674,128 · Granted Oct 22, 2019

Artificial cell constructs for cellular manipulation

Inventors: Steven R. Little (Allison Park, PA); Siddharth Jhunjhunwala (Bengaluru, IN)
Assignees: UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
A61K9/1635A61K9/0019A61K9/1682A61K38/1841A61K38/2013A61K47/6921B01J13/0065B01J2208/00823
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,449,151
App. No.
15/674,128
Granted
Oct 22, 2019
Kind
B2
Abstract

The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (T reg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound T reg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.

Claims (13)

1. A method for treating an inflammatory disease in a subject in need thereof, comprising:

a) identifying an inflammatory disease in said subject, and

b) administering to said subject an artificial particle comprising at least one soluble Treg cell chemokine that is a CCR8 ligand, and a soluble CCL22 chemokine,

whereby reducing at least one symptom of said inflammatory disease.

2. The method of claim 1 , wherein said artificial particle is porous.

3. The method of claim 1 , wherein said artificial particle comprises compartments.

4. The method of claim 3 , wherein said compartments comprise said soluble chemokines.

5. The method of claim 1 , wherein said artificial particle is biodegradable, wherein said soluble chemokines undergo controlled release.

6. The method of claim 5 , wherein said controlled release is a short term release.

7. The method of claim 6 , wherein said short term release is between 30 minutes 24 hours.

8. The method of claim 5 , wherein said controlled release is a long term release.

9. The method of claim 8 , wherein said long term release is between 24 hours-1 year.

10. The method of claim 8 , wherein said long term release is at least one year.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2018
From: JHUNJHUNWALA, SIDDHARTH
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 045397/0516 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2017
From: LITTLE, STEVEN R.
To: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION; MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 043426/0081 →
Continuity (4)
Continuation 14333000 · Jul 16, 2014
Continuation 13383122
Provisional Application 61224571 · Jul 10, 2009
Related Publication 20180021260A1 · Jan 25, 2018